AgomAb Therapeutics NV
-22.7% · 90d
$11.32
+0.27 (+2.44%)
After-Hours $11.32(+0.00)
News
(1)April 2026
Agomab (AGMB) Reports AGMB-445 Phase 1b Trial Progress and €64.8M Cash Position
AGMBAgomab Therapeutics NV
# 🧾 What This Document Is This is AgomAb Therapeutics' **20-F Annual Report**, a comprehensive filing required by the U.S. Securities and Exchange Commission (SEC) for foreign companies like this Belgian biotech. Think of it as the company's official annual "check-up" for U.S. investors, covering
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%